Stockscreener 앱 받기
7.34
0.68%
-0.05
시장 영업 전:
7.36
0.02
+0.27%
전일 마감가:
$7.39
열려 있는:
$7.34
하루 거래량:
50,112
Relative Volume:
0.68
시가총액:
$54.23M
수익:
$7.00M
순이익/손실:
$-56.03M
주가수익비율:
-0.9584
EPS:
-7.6589
순현금흐름:
$-51.79M
1주 성능:
+0.41%
1개월 성능:
-0.81%
6개월 성능:
+20.33%
1년 성능:
+70.70%
1일 변동 폭
$7.30
$7.39
1주일 범위
$7.23
$7.40
52주 변동 폭
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
명칭
Kezar Life Sciences Inc
전화
650-822-5600
주소
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.34 | 54.23M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-10-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Wells Fargo | Outperform |
| 2018-07-16 | 개시 | William Blair | Outperform |
모두보기
Kezar Life Sciences Inc 주식(KZR)의 최신 뉴스
Kezar Life Sciences (KZR) Expected to Announce Earnings on Tuesday - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Pharma Co. Investor Sues Over Misleading Aurinia Deal - Law360
Kezar Life Sciences, Inc. 2025 Executive Compensation, Equity Ownership, and Corporate Governance Overview 171819224546 - Minichart
Kezar Life Sciences (NASDAQ: KZR) details Aurinia tender offer, pay and ownership - Stock Titan
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Large Decrease in Short Interest - MarketBeat
Kezar Life Sciences (KZR) Registration Filing Summary - Quartr
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
KZR Kezar Life Sciences Inc. reports far wider Q4 2025 loss than estimates even as shares edge higher.Revenue Diversification - Cổng thông tin điện tử Tỉnh Sơn La
Kezar Life (KZR) Stock: Reasonably Valued? (Volatility Increases) 2026-04-20Hot Market Picks - Cổng thông tin điện tử tỉnh Tây Ninh
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Are KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders? - Benzinga
M&A Class Action Firm Investigating Multiple Mergers - National Today
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Form 10-KAnnual report [Section 13 and 15(d), not S-K Item 405] - ADVFN
Working capital per share of Kezar Life Sciences Inc – FWB:2KZ0 - TradingView
KZR Technical Analysis & ETF Price Forecast - Intellectia AI
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time - Citeline News & Insights
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - GuruFocus
Weekly Trades: Will Kezar Life Sciences Inc announce a stock splitInsider Buying & Safe Swing Trade Setups - baoquankhu1.vn
Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Published on: 2026-04-10 03:01:28 - baoquankhu1.vn
Sectors Review: What are Kezar Life Sciences Incs recent SEC filings showing2026 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS - Sahm
Is Kezar Life (KZR) Stock Breaking Out | KZR Q4 Earnings: Misses Estimates by $0.74Collaborative Trading Signals - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, CNTA, AFBI, and APLS - Morningstar
Growth Value: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
What limits growth of Kezar Life (KZR) Stock | Price at $7.38, Down 0.14%Stock Ideas - Newser
Are KZR, TALK, WBD Obtaining Fair Deals for their Shareholders? - Finviz
Pullback Watch: What is the next catalyst for Kezar Life Sciences Inc2026 Fed Impact & Precise Entry and Exit Recommendations - baoquankhu1.vn
Shareholder Alert: Ademi LLP investigates whether Kezar - GlobeNewswire
Baselake reports 5.3% stake in Kezar Life Sciences (NASDAQ: KZR) - Stock Titan
Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Volatility Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
KZR Q4 2025 Earnings: Kezar Life Sciences Inc. Misses EPS, No RevenueCrowd Sentiment Stocks - Newser
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - Investing.com South Africa
Kezar Life Sciences Inc (KZR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):